Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Current Leases: 2017-2023

Historic Current Leases for Aclaris Therapeutics (ACRS) over the last 3 years, with Dec 2023 value amounting to $426,000.

  • Aclaris Therapeutics' Current Leases fell 37.72% to $426,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $426,000, marking a year-over-year decrease of 37.72%. This contributed to the annual value of $426,000 for FY2023, which is 37.72% down from last year.
  • Latest data reveals that Aclaris Therapeutics reported Current Leases of $426,000 as of Q4 2023, which was up 37.42% from $310,000 recorded in Q3 2023.
  • In the past 5 years, Aclaris Therapeutics' Current Leases ranged from a high of $766,000 in Q3 2022 and a low of $310,000 during Q3 2023.
  • In the last 3 years, Aclaris Therapeutics' Current Leases had a median value of $643,500 in 2022 and averaged $585,125.
  • Data for Aclaris Therapeutics' Current Leases shows a maximum YoY slumped of 59.53% (in 2023) over the last 5 years.
  • Over the past 3 years, Aclaris Therapeutics' Current Leases (Quarterly) stood at $693,000 in 2021, then dropped by 1.30% to $684,000 in 2022, then slumped by 37.72% to $426,000 in 2023.
  • Its Current Leases stands at $426,000 for Q4 2023, versus $310,000 for Q3 2023 and $458,000 for Q2 2023.